These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 6866997)
1. Spirogermanium: effects on hematopoietic stem cells and survival of normal and tumor-bearing mice. Schwartz GN; Biegel JA; Fisher B; Klein I Proc Soc Exp Biol Med; 1983 Jun; 173(2):176-80. PubMed ID: 6866997 [TBL] [Abstract][Full Text] [Related]
2. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity. Slavik M; Blanc O; Davis J Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870 [TBL] [Abstract][Full Text] [Related]
3. A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse. Schwartz GN; Biegel JA; Boggs SS Leuk Res; 1982; 6(2):269-79. PubMed ID: 7186089 [TBL] [Abstract][Full Text] [Related]
4. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD Cancer Res; 1982 Jul; 42(7):2852-6. PubMed ID: 7200828 [TBL] [Abstract][Full Text] [Related]
6. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells. Saarloos MN; Khoo NK; Lala PK Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293 [TBL] [Abstract][Full Text] [Related]
7. Haemopoietic stem cells in leukaemic AKR mice: the (AKR x C57BL/6)F1 mouse as an in vivo assay system. Schwartz GN; Boggs SS Br J Cancer; 1982 Jun; 45(6):895-903. PubMed ID: 7046778 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions. Mirabelli CK; Badger AM; Sung CP; Hillegass L; Sung CM; Johnson RK; Picker D; Schwartz D; Dorman J; Martellucci S Anticancer Drug Des; 1989 Mar; 3(4):231-42. PubMed ID: 2930625 [TBL] [Abstract][Full Text] [Related]
9. Generation of suppressor cells in normal rats by treatment with spirogermanium, a novel heterocyclic anticancer drug. Badger AM; Mirabelli CK; DiMartino M Immunopharmacology; 1985 Dec; 10(3):201-7. PubMed ID: 2939040 [TBL] [Abstract][Full Text] [Related]
10. Effect of a transplantable leukemia on hematopoietic stem cells in AKR mice. Nakeff A; Valeriote FA Cancer Treat Rep; 1978 May; 62(5):737-41. PubMed ID: 657159 [TBL] [Abstract][Full Text] [Related]
11. Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma. Boros L; Tsiatis AA; Neiman RS; Mann RB; Glick JH Cancer Treat Rep; 1986 Jul; 70(7):917-8. PubMed ID: 3719586 [No Abstract] [Full Text] [Related]
12. Antiarthritic and immunoregulatory activity of spirogermanium. DiMartino MJ; Lee JC; Badger AM; Muirhead KA; Mirabelli CK; Hanna N J Pharmacol Exp Ther; 1986 Jan; 236(1):103-10. PubMed ID: 2934544 [TBL] [Abstract][Full Text] [Related]
13. The effects of chronic administration of cyclophosphamide on haemopoietic stem cells. Pannacciulli IM; Massa G; Saviane AG; Bianchi G; Bogliolo GV; Ghio R Scand J Haematol; 1977 Aug; 19(2):217-23. PubMed ID: 897562 [TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study. Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225 [TBL] [Abstract][Full Text] [Related]
16. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow. Blaauw A; Spitzer G; Dicke K; Drewinko B; Vellekoop L; Zander A Exp Hematol; 1986 Aug; 14(7):683-8. PubMed ID: 2426131 [TBL] [Abstract][Full Text] [Related]
17. Competitive proliferation in the hematopoietic tissues of irradiated hybrid mice engrafted with parental bone marrow and spleen. Muramatsu S; Monnot P; Duplan JF Exp Hematol; 1976 Jul; 4(4):188-200. PubMed ID: 782893 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor growth and metastasis in association with modification of immune response by novel organic germanium compounds. Sato I; Yuan BD; Nishimura T; Tanaka N J Biol Response Mod; 1985 Apr; 4(2):159-68. PubMed ID: 3998767 [TBL] [Abstract][Full Text] [Related]
19. The effect of a Titanocene Dichloride derivative, Ti IV (C5H5)(2) NCS(2), on the haematopoietic response of Ehrlich tumour-bearing mice. Valadares MC; Queiroz ML Eur J Pharmacol; 2002 Mar; 439(1-3):35-42. PubMed ID: 11937090 [TBL] [Abstract][Full Text] [Related]
20. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)]. Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]